Edotreotide
Paraganglioma
Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Excel Diagnostics and Nuclear Oncology Center
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04276597CT.gov Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Paraganglioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edotreotide (this asset) | Excel Diagnostics and Nuclear Oncology Center | P2 | CCC · 52 |
| Oxodotreotide | Fundación de investigación HM | P2 | B |
| Talazoparib | National Cancer Institute (NCI) | P2 | CCC |
| Guadecitabine | National Cancer Institute (NCI) | P2 | CCC |
| Pembrolizumab | M.D. Anderson Cancer Center | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Vinorelbine Ditartrate | University of Southern California | P1 | CC |
| Temsirolimus | University of Southern California | P1 | CC |
+9 more in the Paraganglioma cohort
Other indications for Edotreotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Neuroendocrine Neoplasm | — | P3 | B · 63 |
| Neuroblastoma | — | P2 | B · 60 |
| Carcinoid Tumor | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Edotreotide in Paraganglioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/edotreotide-paraganglioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →